AstraZeneca CEO says lung cancer drug trial data ‘very encouraging’
- The drugmaker’s shares fell by as much as 8 percent earlier this month after the company released interim data from the late-stage clinical trial called TROPION-Lung01
- The company said on Friday it will continue with its plan to file data from the trial with FDA